QGEN - Latest News
Qiagen N.V. (QGEN), operates in Healthcare / Medical - Diagnostics & Research, trades on NYSE.
Market capitalization stands near $8.13B. Trailing twelve-month P/E ratio is 20.29. Beta to the broader market is 0.66.
The article list below shows the most recent QGEN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent QGEN Headlines
Qiagen N.V. (QGEN) Shareholder/Analyst Call Transcript
seekingalpha.com - Jun 24, 2026
Qiagen N. V.
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
seekingalpha.com - Jun 15, 2026
Qiagen N. V.
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use
zacks.com - Jun 15, 2026
QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
businesswire.com - Jun 15, 2026
VENLO, Netherlands & GERMANTOWN, Md. --(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.
A Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75
gurufocus.com - Jun 9, 2026
On June 09, 2026, Qiagen NV (QGEN) shares rose 4. 2% today, bringing the current price to $37.
How News Affects QGEN Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track QGEN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked QGEN news questions
- What is the latest QGEN news headline?
- The most recent QGEN headline (Jun 24, 2026) is "Qiagen N.V. (QGEN) Shareholder/Analyst Call Transcript". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the QGEN news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What QGEN news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual QGEN options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.